Fundraising Fox
/Companies
Sign in

Lassen Therapeutics

Founded 2019 · 10 employees on LinkedIn · 9 known investors

Find your way into Lassen Therapeutics

Sign up to see every warm intro you have to Lassen Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Lassen Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Lassen Therapeutics is a biotechnology company developing therapeutics targeting IL-11, with a pipeline focused on immune and fibrotic diseases.

Biotech

Founders & leadership

Lassen Therapeutics was founded in 2019 by David King.

DKDavid King
David KingCo-Founder & CSOCo-founder and Chief Scientific Officer of Lassen Therapeutics, a biotech company developing therapeutics targeting IL-11 for immune and fibrotic diseases. King has prior experience in biologics and antibody discovery across multiple biotech companies and contributed to the development of FDA-approved therapeutics.
MFMaria Fardis
Maria FardisCEOVenture Partner at Frazier Life Sciences
CCCadmus C. Rich
Cadmus C. RichChief Medical OfficerCadmus C. Rich served as CMO and in advisory roles at multiple pharmaceutical and biotechnology companies, with expertise in ophthalmology and regulatory engagement with the FDA, EMA, and MHRA. He holds board positions at for-profit and not-for-profit organizations.
ESElaine Stracker
Elaine StrackerGeneral CounselElaine Stracker is General Counsel at Lassen Therapeutics. She has held General Counsel roles at multiple biotech and pharmaceutical companies, including experience with licensing, M&A transactions, intellectual property strategy, healthcare compliance, and clinical operations.

Investors · 9

Catalio Capital Management, LPlisted by Catalio Capital Management, LPNew York

How we know: Catalio Capital Management, LP's portfolio page · Not right? Tell us

DC Investment Partnerslisted by DC Investment PartnersMcLean · $10M

How we know: DC Investment Partners's portfolio page · Not right? Tell us

Frazier Life Scienceslisted by Frazier Life SciencesPalo Alto

How we know: Frazier Life Sciences's portfolio page · sdbj.com · Not right? Tell us

Longitude Capitallisted by Longitude CapitalMenlo Park · $10M – $30M

How we know: Longitude Capital's portfolio page · sdbj.com · the VCSheet dataset · Not right? Tell us

Longwood Fundlisted by Longwood FundBoston

How we know: Longwood Fund's portfolio page · funding news · biospace.com · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Biotechnology Value FundreportedSan Francisco

How we know: sdbj.com · Not right? Tell us

Catalio Capital ManagementreportedNew York

How we know: sdbj.com · Not right? Tell us

Frazier Healthcare PartnersreportedSeattle · $50M – $400M

How we know: funding news · biospace.com · Not right? Tell us

Funding

SEC filings, press & company announcements

$85M disclosed across 1 of 3 rounds · 2020–2024

Source: company announcements and press reports — follow each round's link for the claim.

Founder mafia

2 people who came through Lassen Therapeutics went on to found or lead other companies.

David SteinbergBoard MemberFounded Restorbio +3Maria FardisCEOFounded Iovance Biotherapeutics +1

In the news

Lassen Therapeutics Closes $85M Series B Financingfinsmes.com · Dec 2023Lassen Therapeutics Announces Closing of Oversubscribed $85 Million Series B Financing and Announces First Patient Dosed in the Phase 1 Trial Evaluating LASN01 in Thyroid Eye Disease - Lassenlassentherapeutics.com · Dec 2023News - Lassenlassentherapeutics.com · Apr 2020

Frequently asked questions

What does Lassen Therapeutics do?
Lassen Therapeutics is a biotechnology company developing therapeutics targeting IL-11, with a pipeline focused on immune and fibrotic diseases.
Who founded Lassen Therapeutics?
Lassen Therapeutics was founded by David King in 2019.
Who are Lassen Therapeutics's investors?
Lassen Therapeutics's investors include Alta Partners, Catalio Capital Management, LP, DC Investment Partners, Frazier Life Sciences, Longitude Capital, Longwood Fund, Biotechnology Value Fund, Catalio Capital Management and 1 more.
How much funding has Lassen Therapeutics raised?
Lassen Therapeutics has disclosed $85M raised across 1 of its 3 known rounds.